Serum levels of TUBB3 correlate with clinical outcome in Chinese patients with advanced gastric cancer receiving first-line paclitaxel plus capecitabine. (Q50930365)

From Wikidata

Jump to navigation Jump to search

scientific article published on 6 July 2012

Language	Label	Description	Also known as
English	Serum levels of TUBB3 correlate with clinical outcome in Chinese patients with advanced gastric cancer receiving first-line paclitaxel plus capecitabine.	scientific article published on 6 July 2012

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/22766748

Serum levels of TUBB3 correlate with clinical outcome in Chinese patients with advanced gastric cancer receiving first-line paclitaxel plus capecitabine. (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/22766748

1 reference

based on heuristic

inferred from title

author name string

Jingwei Yu

1

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/22766748

Jing Gao

2

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/22766748

Zhihao Lu

3

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/22766748

Yilin Li

4

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/22766748

Lin Shen

5

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/22766748

publication date

6 July 2012

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/22766748

Medical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/22766748

29

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/22766748

5

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/22766748

3029-3034

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/22766748

https://scigraph.springernature.com/pub.10.1007/s12032-012-0292-y

0 references

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0292-Y

21 January 2018

Impact of extended lymphadenectomy on morbidity, mortality, recurrence and 5-year survival after gastrectomy for cancer. Meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0292-Y

21 January 2018

A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0292-Y

21 January 2018

Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0292-Y

21 January 2018

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0292-Y

21 January 2018

Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0292-Y

21 January 2018

A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0292-Y

21 January 2018

Paclitaxel chemotherapy for the treatment of gastric cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0292-Y

21 January 2018

Thymidine Phosphorylase/β-tubulin III expressions predict the response in Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0292-Y

21 January 2018

Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients.

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0292-Y

21 January 2018

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0292-Y

21 January 2018

Hypoxia induces class III beta-tubulin gene expression by HIF-1alpha binding to its 3' flanking region

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0292-Y

21 January 2018

Proteomic characterization of cytoskeletal and mitochondrial class III beta-tubulin

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0292-Y

21 January 2018

Tubulin targets in the pathobiology and therapy of glioblastoma multiforme. I. Class III beta-tubulin

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0292-Y

21 January 2018

High TUBB3 expression, an independent prognostic marker in patients with early non-small cell lung cancer treated by preoperative chemotherapy, is regulated by K-Ras signaling pathway.

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0292-Y

21 January 2018

Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0292-Y

21 January 2018

The predictive and therapeutic value of thymidine phosphorylase and dihydropyrimidine dehydrogenase in capecitabine (Xeloda)-based chemotherapy for head and neck cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0292-Y

21 January 2018

Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0292-Y

21 January 2018

A multi-center, late phase II clinical trial of Genexol (paclitaxel) and cisplatin for patients with advanced gastric cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22766748

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel

1 reference

https://pubmed.ncbi.nlm.nih.gov/22766748

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell

1 reference

https://pubmed.ncbi.nlm.nih.gov/22766748

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Paclitaxel and weekly 24-hour infusion of 5-fluorouracil/folinic acid in advanced gastric cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22766748

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prediction of response to docetaxel by quantitative analysis of class I and III beta-tubulin isotype mRNA expression in human breast cancers.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22766748

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S12032-012-0292-Y

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/22766748

release_fmslhiljmbernjob46pd3gxpym

1 reference

https://api.fatcat.wiki/v0/release/fmslhiljmbernjob46pd3gxpym

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/22766748

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50930365&oldid=1844514634"